Human iPSC-derived Hepatocytes ReproHepateTM for CYP Assay and Drug Toxicity Testing
Poster Mar 20, 2015
Annand R; Akahira R; Tamura K; Inamura M
Pharmaceutical candidate compounds require extended period of time and large amount of development costs before reaching the market. However, for various reasons, most of the candidates will be canceled in their development process. One major reason is hepatotoxicity. Recently, in the beginning of the drug screening process, simple and fast evaluation using cell-based assays has been given great importance in terms of safety and cost reduction. Although human primary hepatocytes have been widely used for hepatotoxicity, problems still remain: lot-to-lot variation, commercial availability and unstable supply. Moreover, there is a great difficulty in executing long-term tests using hepatocytes from the identical donor.
Human-derived iPS cells are pluripotent stem cells with the ability of infinite proliferation and differentiation into various cells including hepatocytes. Therefore, iPS cells enable unlimited production of hepatocytes possessing the same genetic back ground. Furthermore, it is possible to produce various donor-derived hepatocytes since human derived iPS cells can be establish from varied race, sex and genetic back ground.
We found a distinct subpopulation of Tregs within BMSCs. Tregs and BMSCs in co-culture conferred neuroprotection that varied in a dose-dependent manner. Tregs minimized stem cell production of IL-6, a pro-inflammatory cytokine, and inhibited BMSC secretion of FGF-beta, a cytokine related to BMSC proliferation and differentiation. The ratio of Tregs found natively in BMSCs is optimally adapted to provide the maximum neuroprotective benefit of stem cell treatment after ischemic stroke.READ MORE
2nd International Conference on Pharmaceutical Research & Innovations in Pharma Industry
May 30 - May 31, 2019